TABLE 4.
Geometric mean avidity indices of anti-PRP IgG antibodiesa
| Study | Group | No. of subjects tested | GMAI (95% CI) | Statistical difference between groups (P value)b |
|---|---|---|---|---|
| United States | ||||
| Postprimary | DTPa + HBV + OPV + Hib* | 40 | 0.126 (0.106-0.150) | 0.0794 |
| DTPa-HBV-IPV/Hib | 40 | 0.105 (0.094-0.118) | ||
| Prebooster | DTPa + Hib* | 21 | 0.192 (0.143-0.257) | 0.8164 |
| DTPa/Hib | 23 | 0.183 (0.135-0.250) | ||
| Postbooster | DTPa + Hib* | 34 | 0.189 (0.145-0.246) | 0.8067 |
| DTPa/Hib | 37 | 0.182 (0.136-0.193) | ||
| Germany A | ||||
| Postprimary | DTPa + Hib | 33 | 0.094 (0.092-0.096) | 1 |
| DTPa/Hib | 45 | 0.094 (0.094-0.095) | ||
| Prebooster | DTPa + Hib | 21 | 0.292 (0.221-0.387) | 0.0189 |
| DTPa/Hib | 18 | 0.183 (0.138-0.242) | ||
| Postbooster | DTPa + Hib | 31 | 0.252 (0.202-0.313) | <0.0001 |
| DTPa/Hib | 59 | 0.126 (0.115-0.138) | ||
| Myanmar | ||||
| Postprimary | DTPw-HBV/Hib2.5 | 25 | 0.085 (0.070-0.103) | 0.2398 |
| DTPw-HBV/Hib | 25 | 0.069 (0.051-0.094) | ||
| Postbooster | DTPw-HBV/Hib2.5 | 25 | 0.207 (0.167-0.258) | 0.0744 |
| DTPw-HBV/Hib | 25 | 0.283 (0.214-0.374) |
a
Not evaluated in the Germany B study. Blood samples were collected 1 month after the three-dose primary series and before and 4 to 6 weeks after the booster dose. GMAI, geometric mean avidity index; Hib2.5, Hib vaccine containing 2.5 μg PRP conjugated to TT; OPV, oral poliovirus vaccine. *, OmniHIB.
b
Two-sided P value using one-way ANOVA to show a difference between groups.